Evaluation of Von Willebrand Factor in COPD Patients

Overview

Journal J Bras Pneumol

Specialty Pulmonary Medicine

Date 2014 Sep 12

PMID 25210959

Citations 5

Authors

Thiago Prudente Bartholo

Claudia Henrique da Costa

Rogerio Rufino

Affiliations

Soon will be listed here.

Abstract

Objective: To compare the absolute serum von Willebrand factor (vWF) levels and relative serum vWF activity in patients with clinically stable COPD, smokers without airway obstruction, and healthy never-smokers.

Methods: The study included 57 subjects, in three groups: COPD (n = 36); smoker (n = 12); and control (n = 9). During the selection phase, all participants underwent chest X-rays, spirometry, and blood testing. Absolute serum vWF levels and relative serum vWF activity were obtained by turbidimetry and ELISA, respectively. The modified Medical Research Council scale (cut-off score = 2) was used in order to classify COPD patients as symptomatic or mildly symptomatic/asymptomatic.

Results: Absolute vWF levels were significantly lower in the control group than in the smoker and COPD groups: 989 ± 436 pg/mL vs. 2,220 ± 746 pg/mL (p < 0.001) and 1,865 ± 592 pg/mL (p < 0.01). Relative serum vWF activity was significantly higher in the COPD group than in the smoker group (136.7 ± 46.0% vs. 92.8 ± 34.0%; p < 0.05), as well as being significantly higher in the symptomatic COPD subgroup than in the mildly symptomatic/asymptomatic COPD subgroup (154 ± 48% vs. 119 ± 8%; p < 0.05). In all three groups, there was a negative correlation between FEV1 (% of predicted) and relative serum vWF activity (r2 = -0.13; p = 0.009).

Conclusions: Our results suggest that increases in vWF levels and activity contribute to the persistence of systemic inflammation, as well as increasing cardiovascular risk, in COPD patients.

Citing Articles

Biomarkers of Prothrombotic State and Risk Assessment of Exacerbations in Patients with Chronic Obstructive Pulmonary Disease.

Jin Y, Zhu K, Wu S, He S, Cao C Int J Chron Obstruct Pulmon Dis. 2024; 19:2273-2283.

PMID: 39416877 PMC: 11480642. DOI: 10.2147/COPD.S466563.

Assessment of incidence of cerebral vascular diseases and prediction of stroke risk in chronic obstructive pulmonary disease patients using multimodal biomarkers.

Badr M, Elkholy A, Shoeib S, Bahey M, Mohamed E, Reda A Clin Respir J. 2023; 17(3):211-228.

PMID: 36696969 PMC: 9978912. DOI: 10.1111/crj.13587.

Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population.

Kamstrup P, Sand J, Ulrik C, Janner J, Ronn C, Ronnow S Biomedicines. 2022; 10(8).

PMID: 36009558 PMC: 9405886. DOI: 10.3390/biomedicines10082011.

Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk.

Langholm L, Ronnow S, Sand J, Leeming D, Tal-Singer R, Miller B Int J Chron Obstruct Pulmon Dis. 2020; 15:543-552.

PMID: 32210548 PMC: 7069584. DOI: 10.2147/COPD.S235673.

Machine Learning Approach for Predicting Past Environmental Exposures From Molecular Profiling of Post-Exposure Human Serum Samples.

Khan A, Thatcher T, Woeller C, Sime P, Phipps R, Hopke P J Occup Environ Med. 2019; 61 Suppl 12:S55-S64.

PMID: 31800451 PMC: 6897314. DOI: 10.1097/JOM.0000000000001692.

References

Donaldson G, Seemungal T, Patel I, Bhowmik A, Wilkinson T, Hurst J . Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005; 128(4):1995-2004. PMC: 7172405. DOI: 10.1378/chest.128.4.1995. View

Nussbaumer-Ochsner Y, Rabe K . Systemic manifestations of COPD. Chest. 2011; 139(1):165-73. DOI: 10.1378/chest.10-1252. View

Piccirillo L, Goncalves M, Clemente E, Gomes M . [Markers of inflammation in type 1 diabetic patients]. Arq Bras Endocrinol Metabol. 2005; 48(2):253-60. DOI: 10.1590/s0004-27302004000200008. View

Vestbo J, Hurd S, Agusti A, Jones P, Vogelmeier C, Anzueto A . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2012; 187(4):347-65. DOI: 10.1164/rccm.201204-0596PP. View

Topsakal R, Kalay N, Ozdogru I, Cetinkaya Y, Oymak S, Gungor Kaya M . Effects of chronic obstructive pulmonary disease on coronary atherosclerosis. Heart Vessels. 2009; 24(3):164-8. DOI: 10.1007/s00380-008-1103-4. View

MacNee W . Pathogenesis of chronic obstructive pulmonary disease. Clin Chest Med. 2007; 28(3):479-513, v. DOI: 10.1016/j.ccm.2007.06.008. View

Warnier M, Rutten F, Numans M, Kors J, Tan H, de Boer A . Electrocardiographic characteristics of patients with chronic obstructive pulmonary disease. COPD. 2013; 10(1):62-71. DOI: 10.3109/15412555.2012.727918. View

. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013; 37 Suppl 1:S81-90. DOI: 10.2337/dc14-S081. View

Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A . Standardisation of spirometry. Eur Respir J. 2005; 26(2):319-38. DOI: 10.1183/09031936.05.00034805. View

10.

Guarino F, Cantarella G, Caruso M, Russo C, Mancuso S, Arcidiacono G . Endothelial activation and injury by cigarette smoke exposure. J Biol Regul Homeost Agents. 2011; 25(2):259-68. View

11.

Al-Awadhi A, Jadaon M, Alsayegh F, Al-Sharrah S . Smoking, von Willebrand factor and ADAMTS-13 in healthy males. Scand J Clin Lab Invest. 2012; 72(8):614-8. DOI: 10.3109/00365513.2012.725864. View

12.

Polosa R, Cacciola R, Prosperini G, Spicuzza L, Morjaria J, Di Maria G . Endothelial-coagulative activation during chronic obstructive pulmonary disease exacerbations. Haematologica. 2008; 93(8):1275-6. DOI: 10.3324/haematol.12473. View

13.

Moreira G, Manzano B, Gazzotti M, Nascimento O, Perez-Padilla R, Menezes A . PLATINO, a nine-year follow-up study of COPD in the city of São Paulo, Brazil: the problem of underdiagnosis. J Bras Pneumol. 2014; 40(1):30-7. PMC: 4075910. DOI: 10.1590/S1806-37132014000100005. View

14.

Polatli M, Cakir A, Cildag O, Bolaman A, Yenisey C, Yenicerioglu Y . Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis. 2007; 26(2):97-102. DOI: 10.1007/s11239-007-0073-1. View

15.

Rycroft C, Heyes A, Lanza L, Becker K . Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis. 2012; 7:457-94. PMC: 3422122. DOI: 10.2147/COPD.S32330. View

16.

Aibar Arregui M, Laborda Ezquerra K, Lopez F, Lacasa R . [Hypercoagulability state and endotelial injury in stable chronic obstructive pulmonary disease patients]. An Sist Sanit Navar. 2010; 33(1):43-50. View

17.

Thyagarajan B, Jacobs D, Apostol G, Smith L, Lewis C, Williams O . Plasma fibrinogen and lung function: the CARDIA Study. Int J Epidemiol. 2006; 35(4):1001-8. DOI: 10.1093/ije/dyl049. View

18.

Ito K, Barnes P . COPD as a disease of accelerated lung aging. Chest. 2009; 135(1):173-180. DOI: 10.1378/chest.08-1419. View

19.

Pereira C, Sato T, Rodrigues S . New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol. 2007; 33(4):397-406. DOI: 10.1590/s1806-37132007000400008. View

20.

Chambers D, Boldy D, Ayres J . Chronic respiratory symptoms, von Willebrand factor and longitudinal decline in FEV1. Respir Med. 1999; 93(10):726-33. DOI: 10.1016/s0954-6111(99)90040-9. View